{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:35:35Z","timestamp":1791430535786,"version":"4.3.3"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T00:00:00Z","timestamp":1596672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T00:00:00Z","timestamp":1596672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","award":["RC1HL100168"],"award-info":[{"award-number":["RC1HL100168"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Down syndrome (DS) is a congenital disorder caused by trisomy 21 (T21). It is associated with cognitive impairment, muscle hypotonia, heart defects, and other clinical anomalies. At the same time, individuals with Down syndrome have lower prevalence of solid tumor formation. To gain new insights into aberrant DS development during early stages of mesoderm formation and its possible connection to lower solid tumor prevalence, we developed the first model of two types of DS iPSC-derived stromal cells. Utilizing bioinformatic and functional analyses, we identified over 100 genes with coordinated expression among mesodermal and endothelial cell types. The most significantly down-regulated processes in DS mesodermal progenitors were associated with decreased stromal progenitor performance related to connective tissue organization as well as muscle development and functionality. The differentially expressed genes included cytoskeleton-related genes (actin and myosin), ECM genes (Collagens, Galectin-1, Fibronectin, Heparan Sulfate, LOX, FAK1), cell cycle genes (USP16, S1P complexes), and DNA damage repair genes. For DS endothelial cells, our analysis revealed most down-regulated genes associated with cellular response to external stimuli, cell migration, and immune response (inflammation-based). Together with functional assays, these results suggest an impairment in mesodermal development capacity during early stages, which likely translates into connective tissue impairment in DS patients. We further determined that, despite differences in functional processes and characteristics, a significant number of differentially regulated genes involved in tumorigenesis were expressed in a highly coordinated manner across endothelial and mesodermal cells. These findings strongly suggest that microRNAs (miR-24-4, miR-21), cytoskeleton remodeling, response to stimuli, and inflammation can impact resistance to tumorigenesis in DS patients. Furthermore, we also show that endothelial cell functionality is impaired, and when combined with angiogenic inhibition, it can provide another mechanism for decreased solid tumor development. We propose that the same processes, which specify the basis of connective tissue impairment observed in DS patients, potentially impart a resistance to cancer by hindering tumor progression and metastasis. We further establish that cancer-related genes on Chromosome 21 are up-regulated, while genome-wide cancer-related genes are down-regulated. These results suggest that trisomy 21 induces a modified regulation and compensation of many biochemical pathways across the genome. Such downstream interactions may contribute toward promoting tumor resistant mechanisms.<\/jats:p>","DOI":"10.1038\/s41598-020-69418-9","type":"journal-article","created":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T06:04:51Z","timestamp":1596693891000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["iPSC-derived progenitor stromal cells provide new insights into aberrant musculoskeletal development and resistance to cancer in down syndrome"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7949-3471","authenticated-orcid":false,"given":"Yekaterina","family":"Galat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Perepitchka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Elcheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Iannaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip M.","family":"Iannaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3612-098X","authenticated-orcid":false,"given":"Vasiliy","family":"Galat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,6]]},"reference":[{"key":"69418_CR1","doi-asserted-by":"crossref","first-page":"4997","DOI":"10.1073\/pnas.91.11.4997","volume":"91","author":"JR Korenberg","year":"1994","unstructured":"Korenberg, J. R. et al. Down syndrome phenotypes: the consequences of chromosomal imbalance. Proc. Natl. Acad. Sci. U. S. A.91, 4997\u20135001 (1994).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"69418_CR2","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1089\/scd.2010.0578","volume":"21","author":"V Galat","year":"2012","unstructured":"Galat, V. et al. A model of early human embryonic stem cell differentiation reveals inter- and intracellular changes on transition to squamous epithelium. Stem Cells Dev.21, 1250\u20131263 (2012).","journal-title":"Stem Cells Dev."},{"key":"69418_CR3","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1472-6483(10)60810-3","volume":"10","author":"Y Verlinsky","year":"2005","unstructured":"Verlinsky, Y. et al. Human embryonic stem cell lines with genetic disorders. Reprod. Biomed. Online10, 105\u2013110 (2005).","journal-title":"Reprod. Biomed. Online"},{"key":"69418_CR4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.stemcr.2018.05.018","volume":"11","author":"S Bell","year":"2018","unstructured":"Bell, S. et al. Disruption of GRIN2B impairs differentiation in human neurons. Stem Cell Rep.11, 183\u2013196 (2018).","journal-title":"Stem Cell Rep."},{"key":"69418_CR5","doi-asserted-by":"crossref","first-page":"17573","DOI":"10.1073\/pnas.1211175109","volume":"109","author":"ST Chou","year":"2012","unstructured":"Chou, S. T. et al. Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells. Proc. Natl. Acad. Sci. U. S. A.109, 17573\u201317578 (2012).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"69418_CR6","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1038\/s41467-018-07630-y","volume":"9","author":"JC Chiang","year":"2018","unstructured":"Chiang, J. C., Jiang, J., Newburger, P. E. & Lawrence, J. B. Trisomy silencing by XIST normalizes down syndrome cell pathogenesis demonstrated for hematopoietic defects in vitro. Nat. Commun.9, 5180 (2018).","journal-title":"Nat. Commun."},{"key":"69418_CR7","doi-asserted-by":"crossref","first-page":"6102","DOI":"10.1038\/onc.2010.351","volume":"29","author":"S De Vita","year":"2010","unstructured":"De Vita, S. et al. Trisomic dose of several chromosome 21 genes perturbs haematopoietic stem and progenitor cell differentiation in down\u2019s syndrome. Oncogene29, 6102\u20136114 (2010).","journal-title":"Oncogene"},{"key":"69418_CR8","doi-asserted-by":"crossref","first-page":"17567","DOI":"10.1073\/pnas.1215468109","volume":"109","author":"GA Maclean","year":"2012","unstructured":"Maclean, G. A. et al. Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells. Proc. Natl. Acad. Sci. U. S. A.109, 17567\u201317572 (2012).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"69418_CR9","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.celrep.2016.04.031","volume":"15","author":"K Banno","year":"2016","unstructured":"Banno, K. et al. Systematic cellular disease models reveal synergistic interaction of trisomy 21 and GATA1 mutations in hematopoietic abnormalities. Cell Rep.15, 1228\u20131241 (2016).","journal-title":"Cell Rep."},{"key":"69418_CR10","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/blood-2002-12-3904","volume":"101","author":"G Mundschau","year":"2003","unstructured":"Mundschau, G. et al. Mutagenesis of GATA1 is an initiating event in down syndrome leukemogenesis. Blood101, 4298\u20134300 (2003).","journal-title":"Blood"},{"key":"69418_CR11","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.athoracsur.2014.04.075","volume":"98","author":"DL Simpson","year":"2014","unstructured":"Simpson, D. L. et al. Engineering patient-specific valves using stem cells generated from skin biopsy specimens. Ann. Thoracic Surg.98, 947\u2013954 (2014).","journal-title":"Ann. Thoracic Surg."},{"key":"69418_CR12","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1089\/scd.2015.0366","volume":"25","author":"V Galat","year":"2016","unstructured":"Galat, V. et al. Transgene reactivation in induced pluripotent stem cell derivatives and reversion to pluripotency of induced pluripotent stem cell-derived mesenchymal stem cells. Stem Cells Dev.25, 1060\u20131072 (2016).","journal-title":"Stem Cells Dev."},{"key":"69418_CR13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13287-017-0519-0","volume":"8","author":"Y Galat","year":"2017","unstructured":"Galat, Y. et al. Cytokine-free directed differentiation of human pluripotent stem cells efficiently produces hemogenic endothelium with lymphoid potential. Stem Cell Res. Ther.8, 67 (2017).","journal-title":"Stem Cell Res. Ther."},{"key":"69418_CR14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.exphem.2018.05.007","volume":"65","author":"Y Galat","year":"2018","unstructured":"Galat, Y. et al. Application of small molecule CHIR99021 leads to the loss of hemangioblast progenitor and increased hematopoiesis of human pluripotent stem cells. Exp. Hematol.65, 38-48.e31 (2018).","journal-title":"Exp. Hematol."},{"key":"69418_CR15","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1089\/scd.2016.0081","volume":"25","author":"Z Khalkhali-Ellis","year":"2016","unstructured":"Khalkhali-Ellis, Z. et al. Lefty glycoproteins in human embryonic stem cells: extracellular delivery route and posttranslational modification in differentiation. Stem Cells Dev.25, 1681\u20131690 (2016).","journal-title":"Stem Cells Dev."},{"key":"69418_CR16","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/pr.2017.229","volume":"83","author":"PM Iannaccone","year":"2018","unstructured":"Iannaccone, P. M., Galat, V., Bury, M. I., Ma, Y. C. & Sharma, A. K. The utility of stem cells in pediatric urinary bladder regeneration. Pediatr. Res.83, 258\u2013266 (2018).","journal-title":"Pediatr. Res."},{"key":"69418_CR17","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrc3355","volume":"12","author":"D Nizetic","year":"2012","unstructured":"Nizetic, D. & Groet, J. Tumorigenesis in Down\u2019s syndrome: big lessons from a small chromosome. Nat. Rev.12, 721\u2013732 (2012).","journal-title":"Nat. Rev."},{"key":"69418_CR18","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.3389\/fimmu.2018.03058","volume":"9","author":"D Satge","year":"2018","unstructured":"Satge, D. & Seidel, M. G. The pattern of malignancies in down syndrome and its potential context with the immune system. Front. Immunol.9, 3058 (2018).","journal-title":"Front. Immunol."},{"key":"69418_CR19","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/gim.2016.23","volume":"18","author":"H Hasle","year":"2016","unstructured":"Hasle, H., Friedman, J. M., Olsen, J. H. & Rasmussen, S. A. Low risk of solid tumors in persons with Down syndrome. Genet. Med.18, 1151\u20131157 (2016).","journal-title":"Genet. Med."},{"key":"69418_CR20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1471-2407-7-151","volume":"7","author":"SG Baker","year":"2007","unstructured":"Baker, S. G. & Kramer, B. S. Paradoxes in carcinogenesis: new opportunities for research directions. BMC Cancer7, 151 (2007).","journal-title":"BMC Cancer"},{"key":"69418_CR21","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/sj.ejhg.5200721","volume":"9","author":"TS Zorick","year":"2001","unstructured":"Zorick, T. S. et al. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. Eur. J. Hum. Genet.9, 811\u2013814 (2001).","journal-title":"Eur. J. Hum. Genet."},{"key":"69418_CR22","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/ni966","volume":"4","author":"S Ryeom","year":"2003","unstructured":"Ryeom, S., Greenwald, R. J., Sharpe, A. H. & McKeon, F. The threshold pattern of calcineurin-dependent gene expression is altered by loss of the endogenous inhibitor calcipressin. Nat. Immunol.4, 874\u2013881 (2003).","journal-title":"Nat. Immunol."},{"key":"69418_CR23","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1159\/000079832","volume":"41","author":"M Iizuka","year":"2004","unstructured":"Iizuka, M., Abe, M., Shiiba, K., Sasaki, I. & Sato, Y. Down syndrome candidate region 1, a downstream target of VEGF, participates in endothelial cell migration and angiogenesis. J. Vasc. Res.41, 334\u2013344 (2004).","journal-title":"J. Vasc. Res."},{"key":"69418_CR24","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nature09106","volume":"465","author":"LE Reynolds","year":"2010","unstructured":"Reynolds, L. E. et al. Tumour angiogenesis is reduced in the Tc1 mouse model of Down\u2019s syndrome. Nature465, 813\u2013817 (2010).","journal-title":"Nature"},{"key":"69418_CR25","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nature04678","volume":"441","author":"JR Arron","year":"2006","unstructured":"Arron, J. R. et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature441, 595\u2013600 (2006).","journal-title":"Nature"},{"key":"69418_CR26","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1158\/0008-5472.CAN-10-4489","volume":"71","author":"A Yang","year":"2011","unstructured":"Yang, A. & Reeves, R. H. Increased survival following tumorigenesis in Ts65Dn mice that model Down syndrome. Can. Res.71, 3573\u20133581 (2011).","journal-title":"Can. Res."},{"key":"69418_CR27","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/ijc.20532","volume":"113","author":"J Benard","year":"2005","unstructured":"Benard, J., Beron-Gaillard, N. & Satge, D. Down\u2019s syndrome protects against breast cancer: is a constitutional cell microenvironment the key? Int. J. Cancer113, 168\u2013170 (2005).","journal-title":"Int. J. Cancer"},{"key":"69418_CR28","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.stem.2010.11.011","volume":"7","author":"MA Vodyanik","year":"2010","unstructured":"Vodyanik, M. A. et al. A mesoderm-derived precursor for mesenchymal stem and endothelial cells. Cell Stem Cell7, 718\u2013729 (2010).","journal-title":"Cell Stem Cell"},{"key":"69418_CR29","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/jnci\/djt093","volume":"105","author":"SD Finley","year":"2013","unstructured":"Finley, S. D. & Popel, A. S. Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions. J. Natl. Cancer Inst.105, 802\u2013811 (2013).","journal-title":"J. Natl. Cancer Inst."},{"key":"69418_CR30","first-page":"127","volume":"4","author":"S Hua","year":"2013","unstructured":"Hua, S. Targeting sites of inflammation: intercellular adhesion molecule-1 as a target for novel inflammatory therapies. Front. Pharmacol.4, 127 (2013).","journal-title":"Front. Pharmacol."},{"key":"69418_CR31","first-page":"pl1","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal6, pl1 (2013).","journal-title":"Sci. Signal"},{"key":"69418_CR32","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov.2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"69418_CR33","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/s12859-019-3050-8","volume":"20","author":"A Lopez-Rincon","year":"2019","unstructured":"Lopez-Rincon, A., Martinez-Archundia, M., Martinez-Ruiz, G. U., Schoenhuth, A. & Tonda, A. Automatic discovery of 100-miRNA signature for cancer classification using ensemble feature selection. BMC Bioinform.20, 480 (2019).","journal-title":"BMC Bioinform."},{"key":"69418_CR34","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/jcp.22280","volume":"225","author":"S Malchenko","year":"2010","unstructured":"Malchenko, S. et al. Cancer hallmarks in induced pluripotent cells: new insights. J. Cell Physiol.225, 390\u2013393 (2010).","journal-title":"J. Cell Physiol."},{"key":"69418_CR35","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1073\/pnas.0510565103","volume":"103","author":"S Volinia","year":"2006","unstructured":"Volinia, S. et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U. S. A.103, 2257\u20132261 (2006).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"69418_CR36","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10585-019-09966-1","volume":"36","author":"JA Eble","year":"2019","unstructured":"Eble, J. A. & Niland, S. The extracellular matrix in tumor progression and metastasis. Clin. Exp. Metastasis36, 171\u2013198 (2019).","journal-title":"Clin. Exp. Metastasis"},{"key":"69418_CR37","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.3390\/ijms19103028","volume":"19","author":"C Walker","year":"2018","unstructured":"Walker, C., Mojares, E. & Del Rio Hernandez, A. Role of extracellular matrix in development and cancer progression. Int. J. Mol. Sci.19, 3028 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"69418_CR38","doi-asserted-by":"crossref","first-page":"674","DOI":"10.7150\/jca.16901","volume":"8","author":"JP Wang","year":"2017","unstructured":"Wang, J. P. & Hielscher, A. Fibronectin: how its aberrant expression in tumors may improve therapeutic targeting. J. Cancer8, 674\u2013682 (2017).","journal-title":"J. Cancer"},{"key":"69418_CR39","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1007\/s13277-013-1511-7","volume":"35","author":"M Fang","year":"2014","unstructured":"Fang, M., Yuan, J., Peng, C. & Li, Y. Collagen as a double-edged sword in tumor progression. Tumour Biol.35, 2871\u20132882 (2014).","journal-title":"Tumour Biol."},{"key":"69418_CR40","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nrc3792","volume":"14","author":"FJ Sulzmaier","year":"2014","unstructured":"Sulzmaier, F. J., Jean, C. & Schlaepfer, D. D. FAK in cancer: mechanistic findings and clinical applications. Nat. Rev. Cancer14, 598\u2013610 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"69418_CR41","doi-asserted-by":"crossref","first-page":"e0180181","DOI":"10.1371\/journal.pone.0180181","volume":"12","author":"A Begum","year":"2017","unstructured":"Begum, A. et al. The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma. PLoS ONE12, e0180181 (2017).","journal-title":"PLoS ONE"},{"key":"69418_CR42","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.pharmthera.2014.10.001","volume":"146","author":"BY Lee","year":"2015","unstructured":"Lee, B. Y., Timpson, P., Horvath, L. G. & Daly, R. J. FAK signaling in human cancer as a target for therapeutics. Pharmacol. Ther.146, 132\u2013149 (2015).","journal-title":"Pharmacol. Ther."},{"key":"69418_CR43","doi-asserted-by":"crossref","first-page":"521284","DOI":"10.1155\/2012\/521284","volume":"2012","author":"JI Arias","year":"2012","unstructured":"Arias, J. I. et al. The amazing power of cancer cells to recapitulate extraembryonic functions: the Cuckoo\u2019s tricks. J. Oncol.2012, 521284 (2012).","journal-title":"J. Oncol."},{"key":"69418_CR44","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1093\/bioinformatics\/btp536","volume":"25","author":"D Binns","year":"2009","unstructured":"Binns, D. et al. QuickGO: a web-based tool for gene ontology searching. Bioinformatics25, 3045\u20133046 (2009).","journal-title":"Bioinformatics"},{"key":"69418_CR45","doi-asserted-by":"crossref","first-page":"D1057","DOI":"10.1093\/nar\/gku1113","volume":"43","author":"RP Huntley","year":"2015","unstructured":"Huntley, R. P. et al. The GOA database: gene ontology annotation updates for 2015. Nucleic Acids Res.43, D1057-1063 (2015).","journal-title":"Nucleic Acids Res."},{"key":"69418_CR46","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1755-8794-3-40","volume":"3","author":"V Costa","year":"2010","unstructured":"Costa, V. et al. Impairment of circulating endothelial progenitors in Down syndrome. BMC Med. Genom.3, 40 (2010).","journal-title":"BMC Med. Genom."},{"key":"69418_CR47","first-page":"6184185","volume":"2018","author":"N Laforgia","year":"2018","unstructured":"Laforgia, N. et al. A rare case of severe congenital RYR1-associated myopathy. Case Rep. Genet.2018, 6184185 (2018).","journal-title":"Case Rep. Genet."},{"key":"69418_CR48","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1136\/jmg.2003.014274","volume":"41","author":"S Shepherd","year":"2004","unstructured":"Shepherd, S., Ellis, F., Halsall, J., Hopkins, P. & Robinson, R. RYR1 mutations in UK central core disease patients: more than just the C-terminal transmembrane region of the RYR1 gene. J. Med. Genet.41, e33 (2004).","journal-title":"J. Med. Genet."},{"key":"69418_CR49","doi-asserted-by":"crossref","first-page":"e43179","DOI":"10.1371\/journal.pone.0043179","volume":"7","author":"T Bupha-Intr","year":"2012","unstructured":"Bupha-Intr, T., Haizlip, K. M. & Janssen, P. M. Role of endothelin in the induction of cardiac hypertrophy in vitro. PLoS ONE7, e43179 (2012).","journal-title":"PLoS ONE"},{"key":"69418_CR50","first-page":"57","volume":"4","author":"A Dey","year":"2013","unstructured":"Dey, A. et al. Down syndrome related muscle hypotonia: association with COL6A3 functional SNP rs2270669. Front. Genet.4, 57 (2013).","journal-title":"Front. Genet."},{"key":"69418_CR51","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1038\/s41598-018-22342-5","volume":"8","author":"B Pawlikowski","year":"2018","unstructured":"Pawlikowski, B., Betta, N. D., Elston, T., Williams, D. A. & Olwin, B. B. Muscle stem cell dysfunction impairs muscle regeneration in a mouse model of Down syndrome. Sci. Rep.8, 4309 (2018).","journal-title":"Sci. Rep."},{"key":"69418_CR52","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev.biochem.73.011303.073731","volume":"73","author":"I Ishii","year":"2004","unstructured":"Ishii, I., Fukushima, N., Ye, X. & Chun, J. Lysophospholipid receptors: signaling and biology. Annu. Rev. Biochem.73, 321\u2013354 (2004).","journal-title":"Annu. Rev. Biochem."},{"key":"69418_CR53","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fphar.2016.00167","volume":"7","author":"KV Blankenbach","year":"2016","unstructured":"Blankenbach, K. V., Schwalm, S., Pfeilschifter, J. & Meyer Zu Heringdorf, D. Sphingosine-1-phosphate receptor-2 antagonists: therapeutic potential and potential risks. Front. Pharmacol.7, 167 (2016).","journal-title":"Front. Pharmacol."},{"key":"69418_CR54","doi-asserted-by":"crossref","first-page":"32841","DOI":"10.1074\/jbc.M305024200","volume":"278","author":"K Arikawa","year":"2003","unstructured":"Arikawa, K. et al. Ligand-dependent inhibition of B16 melanoma cell migration and invasion via endogenous S1P2 G protein-coupled receptor. Requirement of inhibition of cellular RAC activity. J. Biol. Chem.278, 32841\u201332851 (2003).","journal-title":"J. Biol. Chem."},{"key":"69418_CR55","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1128\/MCB.25.10.4237-4249.2005","volume":"25","author":"SK Goparaju","year":"2005","unstructured":"Goparaju, S. K. et al. The S1P2 receptor negatively regulates platelet-derived growth factor-induced motility and proliferation. Mol. Cell Biol.25, 4237\u20134249 (2005).","journal-title":"Mol. Cell Biol."},{"key":"69418_CR56","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1158\/0008-5472.CAN-04-2311","volume":"65","author":"D Lepley","year":"2005","unstructured":"Lepley, D., Paik, J. H., Hla, T. & Ferrer, F. The G protein-coupled receptor S1P2 regulates Rho\/Rho kinase pathway to inhibit tumor cell migration. Cancer Res.65, 3788\u20133795 (2005).","journal-title":"Cancer Res."},{"key":"69418_CR57","doi-asserted-by":"crossref","first-page":"9247","DOI":"10.1128\/MCB.20.24.9247-9261.2000","volume":"20","author":"H Okamoto","year":"2000","unstructured":"Okamoto, H. et al. Inhibitory regulation of Rac activation, membrane ruffling, and cell migration by the G protein-coupled sphingosine-1-phosphate receptor EDG5 but not EDG1 or EDG3. Mol. Cell Biol.20, 9247\u20139261 (2000).","journal-title":"Mol. Cell Biol."},{"key":"69418_CR58","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/cvr\/cvn118","volume":"79","author":"S Takashima","year":"2008","unstructured":"Takashima, S. et al. G12\/13 and Gq mediate S1P2-induced inhibition of Rac and migration in vascular smooth muscle in a manner dependent on Rho but not Rho kinase. Cardiovasc. Res.79, 689\u2013697 (2008).","journal-title":"Cardiovasc. Res."},{"key":"69418_CR59","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.atherosclerosis.2004.07.032","volume":"178","author":"K Tamama","year":"2005","unstructured":"Tamama, K. et al. High-density lipoprotein inhibits migration of vascular smooth muscle cells through its sphingosine 1-phosphate component. Atherosclerosis178, 19\u201323 (2005).","journal-title":"Atherosclerosis"},{"key":"69418_CR60","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1158\/0008-5472.CAN-09-2722","volume":"70","author":"W Du","year":"2010","unstructured":"Du, W. et al. S1P(2), the G protein-coupled receptor for sphingosine-1-phosphate, negatively regulates tumor angiogenesis and tumor growth in vivo in mice. Cancer Res.70, 772\u2013781 (2010).","journal-title":"Cancer Res."},{"key":"69418_CR61","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0070-2153(06)76007-0","volume":"76","author":"MM Hickey","year":"2006","unstructured":"Hickey, M. M. & Simon, M. C. Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. Curr. Top. Dev. Biol.76, 217\u2013257 (2006).","journal-title":"Curr. Top. Dev. Biol."},{"key":"69418_CR62","doi-asserted-by":"crossref","first-page":"10819","DOI":"10.1074\/jbc.M112.442939","volume":"288","author":"DM Gilkes","year":"2013","unstructured":"Gilkes, D. M., Bajpai, S., Chaturvedi, P., Wirtz, D. & Semenza, G. L. Hypoxia-inducible factor 1 (HIF-1) promotes extracellular matrix remodeling under hypoxic conditions by inducing P4HA1, P4HA2, and PLOD2 expression in fibroblasts. J. Biol. Chem.288, 10819\u201310829 (2013).","journal-title":"J. Biol. Chem."},{"key":"69418_CR63","doi-asserted-by":"crossref","first-page":"e69128","DOI":"10.1371\/journal.pone.0069128","volume":"8","author":"M Vogler","year":"2013","unstructured":"Vogler, M. et al. Hypoxia modulates fibroblastic architecture, adhesion and migration: a role for HIF-1alpha in cofilin regulation and cytoplasmic actin distribution. PLoS ONE8, e69128 (2013).","journal-title":"PLoS ONE"},{"key":"69418_CR64","doi-asserted-by":"crossref","first-page":"6135739","DOI":"10.1155\/2018\/6135739","volume":"2018","author":"L Postovit","year":"2018","unstructured":"Postovit, L., Widmann, C., Huang, P. & Gibson, S. B. Harnessing oxidative stress as an innovative target for cancer therapy. Oxid. Med. Cell Longev2018, 6135739 (2018).","journal-title":"Oxid. Med. Cell Longev"},{"key":"69418_CR65","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12029-019-00232-x","volume":"51","author":"M Maghsudlu","year":"2019","unstructured":"Maghsudlu, M., Farashahi Yazd, E. & Amiriani, T. Increased expression of MiR-27a and MiR-24-2 in esophageal squamous cell carcinoma. J. Gastrointest. Cancer51, 227\u2013233 (2019).","journal-title":"J. Gastrointest. Cancer"},{"key":"69418_CR66","doi-asserted-by":"crossref","first-page":"17981","DOI":"10.1038\/s41598-018-36321-3","volume":"8","author":"S Khalighfard","year":"2018","unstructured":"Khalighfard, S., Alizadeh, A. M., Irani, S. & Omranipour, R. Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients. Sci. Rep.8, 17981 (2018).","journal-title":"Sci. Rep."},{"key":"69418_CR67","doi-asserted-by":"crossref","first-page":"15004","DOI":"10.1038\/sigtrans.2015.4","volume":"1","author":"Y Peng","year":"2016","unstructured":"Peng, Y. & Croce, C. M. The role of MicroRNAs in human cancer. Signal Transduct. Target Ther.1, 15004 (2016).","journal-title":"Signal Transduct. Target Ther."},{"key":"69418_CR68","doi-asserted-by":"crossref","first-page":"e19139","DOI":"10.1371\/journal.pone.0019139","volume":"6","author":"LZ Liu","year":"2011","unstructured":"Liu, L. Z. et al. MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1alpha expression. PLoS ONE6, e19139 (2011).","journal-title":"PLoS ONE"},{"key":"69418_CR69","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/nrc1094","volume":"3","author":"R Kalluri","year":"2003","unstructured":"Kalluri, R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat. Rev. Cancer3, 422\u2013433 (2003).","journal-title":"Nat. Rev. Cancer"},{"key":"69418_CR70","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2353\/ajpath.2006.051321","volume":"168","author":"H Tanjore","year":"2006","unstructured":"Tanjore, H. & Kalluri, R. The role of type IV collagen and basement membranes in cancer progression and metastasis. Am. J. Pathol.168, 715\u2013717 (2006).","journal-title":"Am. J. Pathol."},{"key":"69418_CR71","doi-asserted-by":"crossref","first-page":"11020","DOI":"10.18632\/oncotarget.24280","volume":"9","author":"F Revert","year":"2018","unstructured":"Revert, F. et al. Selective targeting of collagen IV in the cancer cell microenvironment reduces tumor burden. Oncotarget9, 11020\u201311045 (2018).","journal-title":"Oncotarget"},{"key":"69418_CR72","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3390\/ijms17091566","volume":"17","author":"JM Cousin","year":"2016","unstructured":"Cousin, J. M. & Cloninger, M. J. The role of galectin-1 in cancer progression, and synthetic multivalent systems for the study of galectin-1. Int. J. Mol. Sci.17, 1566 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"69418_CR73","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3389\/fendo.2018.00483","volume":"9","author":"A Nagarajan","year":"2018","unstructured":"Nagarajan, A., Malvi, P. & Wajapeyee, N. Heparan sulfate and heparan sulfate proteoglycans in cancer initiation and progression. Front. Endocrinol. (Lausanne)9, 483 (2018).","journal-title":"Front. Endocrinol. (Lausanne)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69418-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69418-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69418-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T11:52:10Z","timestamp":1670327530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69418-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,6]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["69418"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-69418-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,6]]},"assertion":[{"value":"28 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13252"}}